Atlas Trials

Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

Clinical trial NCT07013851 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07013851
Sponsor
Grupo Español de Investigación en Cáncer de Ovario
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
MMRd/MSI-H Stage II-III Endometrial Cancer
Start date
2025-10-01
Primary completion
2029-03-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.